Edwards Lifesciences (NYSE:EW) today unveiled its “Stay in the Race” initiative to support heart valve health.

SAN FRANCISCO--(BUSINESS WIRE)-- Edwards Lifesciences (NYSE: EW) today announced seven-year data from the PARTNER 3 trial, reaffirming the early and sustained patient benefits of Edwards TAVR. The ...

SAPIEN 3, which showed superiority at 1 year, also demonstrates compelling outcomes equivalent to surgery at seven years SAN FRANCISCO--(BUSINESS WIRE)-- Edwards Lifesciences (EW) today announced ...

Add Yahoo as a preferred source to see more of our stories on Google. Edwards Lifesciences’ transcatheter aortic valve replacement (TAVR) system has demonstrated positive results in a long-term trial ...

Edwards Lifesciences (NYSE:EW) reported first-quarter 2026 results that management said came in ahead of expectations, driven ...

Add Yahoo as a preferred source to see more of our stories on Google. Edwards Lifesciences' Sapien 3 Ultra system. The artificial heart valve is pushed through the blood vessels via a catheter and ...

Edwards Lifesciences might be a pioneer in the transcatheter aortic valve replacement market, but that doesn’t mean it’s smooth sailing in the space. The Irvine, CA-based company faces stiff ...

December 14, 2011 (Quebec City, Quebec City) — A small study has shed more light on atrial fibrillation (AF) following transcatheter aortic valve implantation (TAVI) demonstrating, perhaps most ...

Innovation with Purpose, Powered by Science, Centered on Patients: Edwards’ Commitment to Drive Value for the Healthcare Ecosystem IRVINE, Calif.--(BUSINESS WIRE)-- Edwards Lifesciences (NYSE: EW) ...